TITLE

Ophthalmic tech. drive in sector positioning battle

PUB. DATE
November 2007
SOURCE
Medical Technology & Devices Week;11/19/2007, Vol. 5 Issue 46, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This article highlights several factors that makes ophthalmic surgical company Alcon a cornerstone investment in the ophthalmology sector. The company expects to register about $5.5 billion in global revenue for its fiscal year ending December 31, 2007. CEO Carey Rayment stressed Alcon's strong and ongoing commitment to research. Alcon will invest about $3 billion in research and development in the next five years.
ACCESSION #
27566660

 

Related Articles

  • New ophthalmic technologies drive sector positioning battle. Haimovitch, Larry // Medical Device Daily;11/14/2007, Vol. 11 Issue 219, p1 

    The article deals with the highlights of the annual meeting of the American Academy of Ophthalmology in New Orleans, Louisiana. Alcon chairman Carey Rayment started the meeting, citing that he believes Alcon should be viewed as a cornerstone investment. He also stressed firm's strong commitment...

  • News&Notes.  // Review of Optometry;11/15/2002 Supplement, Vol. 139, p2 

    Presents several ophthalmology products in the U.S. Accounts on the labeling clearance claims received by Alcon's Opti-Free Express multi-purpose disinfecting solution; Description of the second generation aspheric multifocal from Blanchard Contact Lens Inc.; Details on the launching of the...

  • Alcon gets FDA approval for LADARVision system.  // Ophthalmology Times;12/1/2002, Vol. 27 Issue 23, p3 

    Announces the U.S. Food and Drug Administration's (FDA) approval of Alcon Inc.'s LADARVision System for customized wavefront-guided laser eye surgery in the treatment of myopia. Explanation of how the system works; Benefits using of the system.

  • System provides benefits of 532-nm continuous-wave treatment beam. Guttman, Cheryl // Ophthalmology Times;3/1/2003, Vol. 28 Issue 5, p33 

    Features the ophthalmology instrument Ophthalas EyeLite Photocoagulator from Alcon. Use of a 532 nanometer diode-pumped frequency-doubled yttrium-argon-gallium (YAG) laser; Laser indirect ophthalmoscope; Slit-lamp delivered photocoagulation procedures.

  • Modified tip design improves liquefacton procedure. Charters, Lynda // Ophthalmology Times;2/15/2003, Vol. 28 Issue 4, p22 

    Features the modified tip design of Aqualase technology with improved liquefaction procedure by Alcon Inc. Susceptibility to denser nuclei; Ability to eliminate ultrasound phacoemulsification for small-incision cataract surgery; Effectiveness in removing cataracts.

  • Alcon Recalls Constellation Vision System.  // Review of Ophthalmology; 

    The article reports the issuance of a Class I recall of Alcon Inc.'s Constellation Vision System after its identification of software and hardware problems that may cause eye injuries such as blindness.

  • Alcon files initial public offering with SEC. Klinec, Joe // Ophthalmology Times;4/1/2002, Vol. 27 Issue 7, p1 

    Reports on the preparations of Nestl � subsidiary Alcon Inc. for an initial public offering (IPO) in the U.S. on April 1, 2002. IPO price; Market trends in ophthalmology; Share of Alcon in the global ophthalmic pharmaceutical market. INSET: Corporate profile.

  • Industry Pipeline.  // Primary Care Optometry News;Apr2008, Vol. 13 Issue 4, p8 

    This section offers news briefs related to the ophthalmology industry in the U.S. The U.S. Food and Drug Administration (FDA) has approved Sonomed's Master-Vu ophthalmic B-scan ultrasound system. Alcon and Landec Corp. has completed clinical trials of its Port Punctum Occluder ophthalmic device,...

  • Novartis' Alcon Gains ex-US Rights to ThromboGenics' Ocriplasmin. Cartwright, Heather // PharmaDeals Review;2012, Vol. 2012 Issue 3, p46 

    Alcon, Novartis' ophthalmic division, has gained exclusive ex-US rights to commercialise ThromboGenics' ocriplasmin for symptomatic vitreomacular adhesion in a deal potentially worth more than €375 M (US$489 M), including €75 M (US$98 M) upfront. Ocriplasmin is under regulatory...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics